What is Nilogen Oncosystems?
Nilogen Oncosystems operates at the intersection of advanced biotechnology and clinical oncology, specializing in the development of innovative 3D cancer models. Utilizing its patented 3D-EXplore technology, the company effectively captures complex tumor heterogeneity directly from fresh human tumor tissue. This capability provides pharmaceutical and biotech partners with unparalleled insights into the tumor microenvironment, facilitating more accurate biomarker discovery and the refinement of cell therapies. By bridging the gap between preclinical research and clinical application, Nilogen Oncosystems empowers drug developers to optimize therapeutic responses and increase the probability of success in high-stakes clinical trials.
How much funding has Nilogen Oncosystems raised?
Nilogen Oncosystems has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
Key Investors in Nilogen Oncosystems
PPP
Public-Private Partnership
What's next for Nilogen Oncosystems?
With the infusion of this recent capital, Nilogen Oncosystems is poised to scale its operational capacity and expand its service offerings within the immuno-oncology landscape. The strategic focus will likely center on enhancing its bioinformatics infrastructure and broadening the application of its 3D-EXplore platform to support a wider array of drug development pipelines. As the industry shifts toward more personalized treatment modalities, the company's ability to provide high-fidelity data on human tumor responses will be critical. Future growth will likely involve deepening partnerships with global pharmaceutical entities and potentially exploring new therapeutic indications to address unmet needs in cancer care.
See full Nilogen Oncosystems company page
